LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
Agreement signedPublished 5 May 2022

Advanz Pharma /
Intercept’s international operations

Advanz Pharma to take on Intercept’s international operations outside the U.S.

Price
$405m
Stage
Agreement signed
Source · 5 May 2022
See the source
01 / BuyerAdvanz Pharma
02 / TargetIntercept’s international operations
01

What happened

Intercept Pharmaceuticals, Inc. agreed to sell certain foreign subsidiaries and rights regarding its international operations to Advanz Pharma, including a license to commercialize Ocaliva outside the U.S.

The agreements provide for $405 million up front, with an additional $45 million earnout tied to extensions of orphan drug exclusivity in Europe.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Advanz Pharma to take on Intercept’s international operations outside the U.S.

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.